Total number of publications: 1244
2025
-
Abelacimab versus Rivaroxaban in Patients with Atrial Fibrillation
New England journal of medicine, year: 2025, volume: 392, edition: 4, DOI
-
Optimizing beta-blocker therapy in chronic heart failure: a real-world study of patients with and without atrial fibrillation
POSTGRADUATE MEDICINE, year: 2025, volume: 137, edition: 8, DOI
2024
-
ANTIHYPERTENSIVE DRUGS IN CHRONIC HEART FAILURE IN THE CZECH REPUBLIC, FOCUSING ON BETA-BLOCKERS
Year: 2024, type: Conference abstract, DOI
-
Diabetes mellitus in stable chronic heart failure and the combination with humoral activation, their association, and prediction of 2-year adverse outcomes. Data from the FAR NHL registry
JOURNAL OF DIABETES, year: 2024, volume: 16, edition: 9, DOI
-
Polymorphic Variants of SCN5A Gene (rs41312433 and rs1805124) Associated with Coronary Artery Affliction in Patients with Severe Arrhythmias
GENES, year: 2024, volume: 15, edition: 2, DOI
2023
-
Diabates mellitus u chronického srdečního selhání a kombinace s natriuretickým peptidem jako prediktor dvouleté prognózy
Year: 2023, type: Appeared in Conference without Proceedings
2022
-
Comparison of Patients with Reduced and Mildly Reduced Left Ventricular Ejection Fraction: Intermediate Data from the FAR NHL Registry
Applied Sciences, year: 2022, volume: 12, edition: 21, DOI
-
Empagliflozin benefits in patients with heart failure and preserved ejection fraction
NATURE MEDICINE, year: 2022, volume: 28, edition: 12, DOI
-
Multicentrická, observační, prospektivní studie zaměřená na úroveň diagnostiky a léčby chronického srdečního selhání v České republice – MOST HF. Zdůvodnění a uspořádání studie
cor et Vasa, year: 2022, volume: 64, edition: 6, DOI
-
Obesity and effects of dapagliflozin on cardiovascular and renal outcomes in patients with type 2 diabetes mellitus in the DECLARE–TIMI 58 trial
European Heart Journal, year: 2022, volume: 43, edition: 31, DOI